Compare Kroger Co (KR) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs Mesoblast Limited — how do they compare? Kroger Co trades at $61.43 (market cap $36.27B), while Mesoblast Limited trades at $14.24 (market cap $1.75B). The key difference: Kroger Co is far larger — about 20.7× Mesoblast Limited's market cap, and Kroger Co pays a 2.54% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kroger Co for 108 Days and Mesoblast Limited for 15 Days on average.
| KR | MESO | |
|---|---|---|
Market Cap | $36.27B | $1.75B |
Volume | 8,301,523 | 239,027 |
Sector | Consumer Staples | Health |
52-Week High | $75.60 | $20.96 |
52-Week Low | $55.53 | $13.19 |
Typical Hold Time | 108 Days | 15 Days |
Enterprise Value | $57.69B | $1.83B |
Dividend Yield | 2.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $61.04, up 3.02% with a bullish technical signal and strong analyst support. The stock shows solid fundamentals with $147.12B revenue, 14.24% ROE, and consistent dividend payments. Recent earnings beat expectations in two of the last three quarters, while the company demonstrates strong cash flow generation with $5.79B from operations in 2025. Technical indicators show the stock trading near pivot point resistance at $62 with bullish moving average alignment.
Kroger presents a compelling value opportunity with low P/S ratio of 0.26 and 47.7% analyst buy ratings, though near-term risks include integration challenges from the Giant Eagle acquisition and cost pressures. The consensus price target of $70.62 suggests 15.7% upside potential, supported by digital growth initiatives and retail media expansion, but investors should monitor identical sales trends and margin pressures in the competitive grocery sector.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
